Terrestrial Bio has dosed the first patients in a Phase I clinical trial evaluating its patch that delivers GLP-1 therapeutic ...

The Applied Biosystems™ SwiftArrayStudio™ Microarray Analyzer from Thermo Fisher Scientific is designed for fast, scalable sample analysis. Paired with the Applied Biosystems Axiom™ PharmacoPro™ Array ...

Definition: A microarray is a small, flat substrate carrying an ordered grid of microscopic probe features, each containing a known biological molecule, that is used to measure many molecular targets ...

Electrical and Computer Engineering Department and Physics Department, Boston University, Boston, Massachusetts 02215, and Istituto di Chimica del Riconoscimento Molecolare, CNR, Milano, Italy * To ...

Abstract: We have developed eight-DFB-LD-array WSLs having a novel integration structure that uses a selectively-grown microarray active waveguides directly connected to dry-etched passive waveguides.

cDNA microarray is an innovative technology that facilitates the analysis of the expression of thousands of genes simultaneously. The utilization of this methodology, which is rapidly evolving, ...

Thermo Fisher Scientific has introduced the Applied Biosystems™ SwiftArrayStudio™ Microarray Analyzer, designed for fast and scalable sample analysis. In conjunction with two new arrays – the Applied ...

Microarray technology encompasses a few relatively well-established methods and numerous applications that are in various stages of development. Apart from their use as a tool for diagnostic testing ...

Reported Data Supports the Potential Extension of HD-MAP Vaccine Delivery to Oncology Indications Recently published data generated by researchers at The University of Queensland and Vaxxas shows ...

The clinical study aims to evaluate a vaccine for avian influenza A (H7N9) delivered by Vaxxas’ high-density microarray patch (HD-MAP), and is funded by the United States government as a potential ...

Innovative vaccine products will be critical in helping to address the existing implementation barriers that have prevented the achievement of the measles and rubella (MR) vaccine coverage targets.